Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05668884
Other study ID # 2209260-22
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date October 18, 2022
Est. completion date March 31, 2025

Study information

Verified date December 2022
Source Fudan University
Contact Lu Wang, M.D.
Phone 86-18121299357
Email w.lr@hotmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In this phase 2 study, the investigators aim to evaluate the effects and safety of combined therapy using oxaliplatin and gemcitabine chemotherapy, Donafenib and Tislelizumab for patients with advanced biliary tract carcinoma.


Description:

Most advanced biliary tract carcinoma (BTC) patients are often accompanied by local or distant metastases and lose the opportunity for surgical resection. For patients with advanced BTC who have been in stages III and IV (AJCC/UICC, V2, 2018), the survival time is less than 4 months, and there is currently no standard treatment. The Gemox chemotherapy (oxaliplatin + gemcitabine) has been used in the treatment of advanced BTC, but the efficacy is still unsatisfactory. Donafenib is a small molecule multi-kinase inhibitor, the main targets including VEGFR1-3, PDGFRα, RET(ret proto-oncogene ), c-KIT(KIT proto-oncogene, receptor tyrosine kinase), Raf,FLT3,have anti-angiogenic effects, have been proven effective in hepatocellular carcinoma. In recent years, monoclonal antibodies against programmed cell death protein 1 (PD1) have shown remarkable therapeutic effects in the treatment of various solid tumors. Prior to this, the combined treatment of GEMOX combined with Donafenib and Tislelizumab was proved satisfying safety. Meanwhile,the phase-I trial showed good efficacy in conversion rate and 6-month overall survival rate. Due to the limitted small sample size of the phase I trial, the investigators aim to expand the sample size to further verify the effects and safety of combined therapy in the study.


Recruitment information / eligibility

Status Recruiting
Enrollment 35
Est. completion date March 31, 2025
Est. primary completion date September 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Age =18 years and =75 years; - ECOG physical condition score: 0~1; - Histologically or cytologically confirmed advanced biliary tract carcinoma (including gallbladder, intrahepatic and extrahepatic cholangiocarcinoma); - Preoperative imaging assessment of the disease stage was III/IV; - At least one measurable lesion (according to mRECIST criteria) - Child-Pugh classification : A or B - The main organs function well, and the examination indicators meet the following requirements: - Routine blood tests: Hemoglobin =90 g/L (no blood transfusion within 14 days);Neutrophil count =1.5×10^9/L; Platelet count =80×10^9/L; - Biochemical examination: Total bilirubin =2×ULN (upper normal value); ALT or AST = 2.5×ULN; Endogenous creatinine clearance = 50 mL /min (Cockcroft-Gault formula); - thyroid function:Thyroid function is normal, thyroid stimulating hormone TSH is defined to be within the normal range. If baseline TSH is outside the normal range, T3 and T4 can be included if they are within the normal range; - Myocardial enzyme profile:The myocardial enzyme profile was in the normal range (if simple laboratory abnormalities that were not clinically significant as determined by the investigators could also be included); - Estimated survival time = 3 months; - Sign the informed consent voluntarily; - Good compliance, and family members willing to cooperate with follow-up. Exclusion Criteria: - Patients with other uncured malignant tumors; - Pregnant or lactating women who are required to withdraw from the clinical trial if they become pregnant during the study period; - Previous antitumor therapy for the disease in this study; - Participated in clinical trials of other drugs within one month; - Patients with a known history of other systemic serious diseases before screening; - Obstructive jaundice (after active treatment such as biliary drainage or stent, the patients can be included in the group after the liver function returns to normal); - Untreated active hepatitis B (defined as HBsAg positive and HBV-DNA copy number greater than the upper limit of normal in the clinical laboratory of the study center); - Active HCV infected persons (HCV antibody positive with HCV RNA levels above the lower limit of detection); - Allergic to any investigational drug or excipient; - Long-term unhealed wounds or incomplete healing fractures; - Previous organ transplantation history; - Abnormal coagulation function; - Screening for overactivity/venous thrombosis events in the previous year, such as cerebrovascular accidents (including temporary ischemic attacks), deep vein thrombosis and pulmonary embolism; - Having a history of abuse of psychotropic substances and being unable to quit or having mental disorders; - A history of immune deficiency or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation; - Concomitant conditions that, in the investigator's judgment, seriously endanger the patient's safety or affect the patient's completion of the study.

Study Design


Related Conditions & MeSH terms


Intervention

Combination Product:
Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab
Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab every 3 weeks

Locations

Country Name City State
China Fudan University Shanghai Cancer Center Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Fudan University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall response rate objective response rate(ORR),defined as percentage of participants achieving assessed complete response (CR) and partial response (PR) by the investigator according to the RECIST 1.1 6 months
Primary Conversion rate Conversion rate, defined as the percentage of the conversion of patients with BTC assessed as unresectable into resectable through interventions, including the conversion of unresectable into resectable in the scientific sense such as insufficient future liver remnant(FLR), as well as the conversion of R1 and R2 to R0. 6 months
Secondary 1-year Recurrence free survival 1-year Recurrence free survival 1 year
Secondary Progression-free survival progression-free survival(PFS), defined as the time from enrollment to the first documented disease progression or death due to any cause, whichever occurs first. Responses are according to the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by investigator 6 months
Secondary Overall survival overall survival(OS), defined as the time from enrollment to death due to any cause. 6 months
Secondary Incidence and degree of Adverse Events and Serious Adverse Events Incidence, severity, and relationship to study drugs of all adverse events (AEs), treatment-related adverse events (TRAEs), and serious adverse events (SAEs). 6 months
See also
  Status Clinical Trial Phase
Terminated NCT04003896 - A Study to Evaluate Abemaciclib in Advanced Biliary Tract Carcinoma Phase 2
Active, not recruiting NCT04003636 - Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966) Phase 3
Not yet recruiting NCT05064852 - A Real-world Study of the Safety and Efficacy of Surufatinib in the Treatment of Biliary Tract Carcinoma
Recruiting NCT05123482 - A Phase I/IIa Study of AZD8205 Given Alone or in Combination With Anticancer Drugs, in Participants With Advanced or Metastatic Solid Malignancies Phase 1/Phase 2
Active, not recruiting NCT02151084 - A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer Phase 2
Recruiting NCT06048133 - Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC) Phase 2
Recruiting NCT05845554 - Application of Chromosomal Instability in Early Diagnosis of Biliary Tract Carcinoma
Completed NCT00490399 - Trial of Gemcitabine and Cisplatin in Patients With Inoperable Biliary Tract Carcinomas Phase 2
Completed NCT04067960 - Pharmacogenomics Testing in Directing the Optimal Use of Supportive Care Medications in Patients With Stage III-IV Cancer Early Phase 1
Not yet recruiting NCT06430827 - Clinical Study of Irinotecan Hydrochloride Liposome Combined With Capecitabine for Second-line Treatment in Patients With Advanced or Metastatic Biliary Tract Carcinoma Phase 2
Withdrawn NCT02105350 - A Study of MEK162 With Gemcitabine and Oxaliplatin in Biliary Cancer Phase 1
Recruiting NCT06047990 - Endobiliary Percutaneous Cryobiopsy in Malignant Biliary Obstruction N/A
Active, not recruiting NCT04924062 - Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)-China Extension Study Phase 3
Not yet recruiting NCT06463548 - Irinotecan Hydrochloride Liposome Combined With Capecitabine and Lenvatinib in Patients With Biliary Tract Carcinoma N/A
Terminated NCT04178460 - A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment Phase 1
Completed NCT03027284 - A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer Phase 1
Recruiting NCT06199882 - SBRT Sequential Surufatinib Combined With Immunotherapy for Biliary Tract Carcinoma Phase 2
Active, not recruiting NCT05023109 - GP Chemotherapy in Combination With Anti-PD-1 and Anti-TIGIT in Unresectable Advanced BTC Phase 2
Not yet recruiting NCT06168292 - Intraductal Radiofrequency Thermoablation and Radiotherapy Combined Treatment for Extrahepatic Cholangiocarcinoma N/A
Recruiting NCT04979663 - GEMOX Combined With Donafenib and Tislelizumab in Biliary Tract Cancer Phase 1/Phase 2